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Abstract:  Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is an important cause of severe 
pulmonary hypertension (PH). D-dimer, a degradation product of fibrin, has been used as a marker for various diseases. In 
patients with idiopathic pulmonary arterial hypertension there is evidence to suggest that D-dimer levels are associated 
with disease severity; however, data regarding D-dimer in patients with CTEPH are lacking. 
Objective: To assess the significance of D-dimer in patients with CTEPH. 
Patients and Methods: Retrospective chart review of 618 patients seen at our PH clinic from 1991 to June 2008. Data 
collection focused on patients diagnosed with CTEPH, D-dimer levels, demographics, clinical, and hemodynamics. We 
compared D-dimer levels in CTEPH patients or World Health Organization (WHO) diagnostic group 4 with PH patients 
in WHO group 1. 
Results: Thirty-four patients with confirmed CTEPH were identified, of these 19 had D-dimer levels and 7 were positive. 
Of the 234 patients in WHO group 1 excluding patients with portopulmonary hypertension (n = 54) and pulmonary veno-
occlusive disease (n = 2) 97 had D-dimer levels and 52 were positive. We found an estimated sensitivity of the D-dimer 
test in diagnosing CTEPH was 37% while the estimated specificity was 46%. The positive predictive value and negative 
predictive value were 12% and 79% respectively. 
Conclusion: D-dimer is an insensitive and nonspecific test for the diagnosis of CTEPH. Despite a high negative predictive 
value D-dimer alone cannot be used to rule out CTEPH in patients with PH. 
INTRODUCTION 
 Chronic thromboembolic pulmonary hypertension 
(CTEPH) is an important cause of severe pulmonary 
hypertension associated with significant morbidity and 
mortality [1]. The exact incidence of CTEPH is not known 
with certainty but historically been estimated to occur in 0.1-
0.5% of patients who survive an episode of pulmonary 
embolism [2, 3]. One recent study by Becattini reported an 
incidence of about 1% [4],  while Pengo and colleagues 
found evidence of CTEPH in 3.8% of patients within two 
years after a first episode of symptomatic pulmonary 
embolism [5]. D-dimer, a degradation product of cross-
linked fibrin, has been used as a marker for various diseases 
[6, 7]. In patients with idiopathic pulmonary arterial 
hypertension (IPAH) there is evidence to suggest that D-
dimer levels are associated with disease severity. Shitrit   
et al. looked at 14 patients with IPAH and found that D-
dimer levels were positively correlated with New York Heart 
Association (NYHA) functional class, pulmonary artery 
pressure, and survival [8]. The same group separately 
reported that the mean ELISA D-dimer levels were 
significantly higher in the IPAH group compared with the 
matched control group [9]. The findings in IPAH have a 
sound basis as thrombosis-in-situ [10] may play a key role in  
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the pathogenesis [11]. In contrast, CTEPH probably occurs 
as a result of incomplete resolution of pulmonary emboli 
[12]. Eventually, the clot becomes incorporated into the 
pulmonary arterial wall leading to increased pulmonary 
vascular resistance and hypertension. Furthermore, fibrin 
derived from patients with CTEPH seems resistant to lysis 
[13]. 
  Data regarding D-dimer levels in patients with CTEPH 
are lacking. Given the chronic and fibrotic nature of vascular 
obstruction, we hypothesized that D-dimer levels would not 
correlate with CTEPH when compared with patients that 
have PH not due to chronic thromboembolism. 
PATIENTS AND METHODS 
  After approval by our institutional review board a 
retrospective chart review of 618 patients seen at the 
pulmonary hypertension (PH) clinic at the Mayo Clinic, 
Jacksonville from 1991 to June 2008 was conducted. 
  Data collection focused on age on date of PH evaluation, 
gender, race, World Health Organization (WHO) functional 
classification and diagnostic group [14], and D-dimer level. 
  Pulmonary hypertension was defined as the presence of a 
mean pulmonary arterial pressure of greater than 25 mmHg 
at rest or 30 mmHg with exercise at catheterization [15] or 
an estimated right ventricular systolic pressure greater than 
35 mmHg by echocardiogram [16]. 
  D-dimer levels that were collected prior to February 2003 
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semi-quantitative with a normal range of <250 μg/L. 
Thereafter, D-dimer was performed utilizing the 
turbidimetric titration assay with a normal range of  0.4 
μg/ml. An elevated D-dimer level using the appropriate 
normal range for each test was considered to be positive. 
  Patients with CTEPH were diagnosed based on positive 
ventilation and perfusion (V/Q) lung scan [17], positive CT 
angiography, and/or by pulmonary arterial angiographic 
evidence of chronic thromboembolism. If V/Q scan was the 
primary mode of diagnosis, it was required to be high 
probability for thromboembolic disease in order to be 
considered a positive test for CTEPH. A negative CT 
angiogram was not considered sufficient to exclude CTEPH. 
For patients with WHO group 1 chronic thromboembolism 
was excluded via V/Q lung scan. 
  Numerical variables were summarized with the sample 
median, minimum, 25
th percentile, 75
th percentile, and 
maximum. Categorical variables were summarized with 
number and percentage. Patient characteristics were 
compared between CTEPH and WHO group 1 patients using 
Fisher’s exact test or a Wilcoxon rank sum test. Logistic 
regression was used to investigate the association between 
D-dimer test results (positive vs negative) and diagnosis 
group (WHO group 1 vs CTEPH WHO group 4); a single 
variable model was considered as well as a multivariate 
model adjusted for age and sex. Sensitivity, specificity, 
positive predictive value (PPV), and negative predicted value 
(NPV) were estimated along with exact binomial 95% 
confidence intervals (CIs). Statistical analyses were 
performed using SPLUS (version 8.0.1; Insightful 
Corporation, Seattle, Washington). 
RESULTS 
  Thirty-four patients with confirmed CTEPH based on 
positive V/Q lung scan, CT angiography, and/or by 
pulmonary arterial angiogram were identified. Nine patients 
(26%) had a high probability V/Q scan alone, 5 (15%) had a 
positive CT angiogram alone, and 8 (24%) had a positive 
pulmonary arterial angiogram alone. There were 12 (35 %) 
patients who had a combination of positive tests. 
  Nineteen of 34 (56%) CTEPH patients had D-dimer 
levels of which 7 were positive (37%). Table 1 compares the 
clinical and hemodynamic characteristics of the patients with 
available D-dimer levels in CTEPH and WHO group 1 or 
pulmonary arterial hypertension (PAH) excluding patients 
with portopulmonary hypertension (n = 54) and pulmonary 
veno-occlusive disease (n = 2). Ninety seven of 234 (41%) 
patients in WHO group 1 had D-dimer levels available. 
 The only statistically significant difference in 
demographics (age, race and sex) was that there were more 
men in the CTEPH group compared to WHO group 1 
patients. Most patients were WHO functional class III or IV 
in both groups. The six-minute walk distance was also 
similar in both groups. Echocardiogram was performed on 
all patients and there was no difference between the two 
groups in the estimated pulmonary artery systolic pressure. 
Most patients in each group had right heart catheterization 
with similar hemodynamic results. 
 
  The patients who had D-dimer testing are compared in 
Table 2. In single variable analysis, there is no evidence of a 
difference in the proportion of positive D-dimer tests 
between CTEPH and WHO group 1 patients (37% vs 54%, p 
= 0.19). These findings remain consistent after adjusting for 
age and sex (p = 0.19). The estimated sensitivity of the D-
dimer test in diagnosing CTEPH was 37% (95% CI: 16%-
62%), while the estimated specificity was 46% (95% CI: 36-
57%). The estimated PPV was 12% (95% CI: 5%-23%), 
while the NPV was 79% (95% CI: 66-89%). 
    The D-dimer test was performed in only 116 of the 
original 268 patients considered. When we compared 
patients with a D-dimer test to those patients without a D-
dimer test for CTEPH and WHO group 1 patients separately, 
we noted no meaningful differences except that CTEPH 
patients with a D-dimer test were male more often than 
CTEPH patients without a D-dimer test (Table 3). Overall, 
patient characteristics appear similar between patients with 
and without a D-dimer test performed except for sex in 
CTEPH patients. 
DISCUSSION 
  It has been suggested that CTEPH is an extension of the 
natural history of acute pulmonary embolic disease but it 
occurs only in a minority of patients after acute embolism 
[12, 18, 19]. However, CTEPH may occur in the absence of 
a clear history of acute pulmonary embolism [20]. Even in 
patients receiving appropriate treatment for an acute 
pulmonary embolism incomplete resolution occurs in a 
significant number of patients placing them at risk for 
developing CTEPH [21]. The occurrence of CTEPH 
portends a poor prognosis and if left untreated the 
probability of survival for 5 years is only 30% when the 
mean pulmonary artery pressure is >40 mmHg [22]. Because 
CTEPH is associated with significant morbidity and 
mortality, the recognition of patients who are at risk has been 
challenging. The prevalence of thrombophilic states in 
patients with established CTEPH has shown to be no 
different than in patients who have IPAH or control subjects 
[23, 24]. However some reports suggest that an underlying 
hypercoagulable state may be responsible for the 
development of CTEPH. One study by Bonderman and 
colleagues [25] showed increased levels of factor VIII in 
41% of patients with CTEPH compared to 5% of normal 
controls. Antiphospholipid antibodies, another possible 
prothrombotic finding have been identified in up to 21% of 
patients who have CTEPH [22]. D-dimer assay, a specific 
marker for crossed linked fibrin is often used as a marker for 
thromboembolic disease. As mentioned previously in 
patients with IPAH there is evidence to suggest that D-dimer 
levels are associated with the status of disease severity [8, 9]. 
However, in 47 patients with PAH and systemic sclerosis 
according to a study by Kiatchoosakun and colleagues D-
dimer levels was not associated with hemodynamic 
measurements made by echocardiogram [26]. In patients 
with CTPEH, the thromboembolic phenomenon is chronic 
and fibrotic in nature; therefore D-dimer levels may be less 
indicative of active disease. The clot eventually becomes 
incorporated into the pulmonary arterial wall leading to less 
exposed fibrin products available for detection. 
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Table  2.  D-Dimer Results According in CTEPH and WHO 
Group 1 Patients 
 
D-Dimer Test Result  CTEPH (N = 19)  WHO Group 1 (N = 97) 
Positive  7 (37%)  52 (54%) 
Negative  12 (63%)  45 (46%) 
CTEPH = chronic thromboembolic pulmonary hypertension; WHO = World Health 
Organization. 
 
  Our study shows that the ability of D-dimer to detect for 
CTEPH is insensitive even with a high negative predictive 
value which supports our hypothesis and the above 
postulated mechanism for CTEPH. We also could not find a 
statistical difference in the proportion of the positive D-
dimer tests between CTEPH and WHO group 1 patients. 
  Conversely, the pathophysiology of PAH involves 
thrombosis in situ in a significant number of patients [12, 27, 
28]. Indeed, a relationship between elevated D-dimer levels 
and the severity and prognosis of PAH has been 
demonstrated [8, 9]. In both studies [8, 9] by Shitrit et al. the 
majority of the PAH patients were women and most had 
class III or IV symptoms similar to our population. In our 
group of CTEPH patients there was slightly more males than 
females in the group with available D-dimer. However, in 
the CTEPH patients overall there was still a predominance of 
females (20 out of 34 or 59%). Other characteristics 
appeared similar in both groups with or without D-dimer 
testing including hemodynamic values. 
  D-dimer may not be an attractive test for screening for 
CTEPH but may have other implications including prognosis 
value which was not evaluated in our study. 
  This study has several limitations. It is retrospective and 
single-center in design. Due to the relatively small sample 
size, there is a lack of power to detect an association between 
D-dimer test result and diagnosis group (CTEPH WHO 
group 4 vs WHO group 1). Thus, there may be an association 
between these two variables that this study did not have 
enough power to detect. Secondly, the study was performed 
in a tertiary care center which could likely differ from other 
centers or in a primary care setting where D-Dimer is used as 
a screening test. Not all patients had D-dimer testing but the 
patients who did not seem similar in demographic and 
clinical characteristics which may lessen the likelihood of 
bias. Furthermore, there were two methods of testing for D-
Dimer during the study period which could have different 
sensitivities or specificities in detecting CTEPH. Analyzing 
data from only one method of testing was felt that the power 
of the study would be insufficient due to the overall low 
number of patients having available D-Dimer values. 
However, we did interpret the tests results as positive and 
negative as opposed to using absolute values which cannot 
be compared head to head to reduce testing method bias. 
Another point worth mentioning is that the majority of 
Table 1.  Patient Characteristics 
 
Variable  CTEPH (N = 19)  WHO Group 1 (N = 97)  P-Value 
Age  71 (31, 63, 74, 81)  64 (21, 53, 73, 88)  0.18 
Sex (Male)  10 (53%)  20 (21%)  0.008 
Race     0.11 
Caucasian  15 (79%)  90 (93%)   
African American  4 (21%)  6 (6%)   
Other  0 (0%)  1 (1%)   
WHO class     0.75 
1  1 (5%)  4 (4%)   
2  3 (16%)  24 (25%)   
3  13 (68%)  56 (58%)   
4  2 (11%)  13 (13%)   
Six minute walk test (meters)  319 (126, 266, 407, 460)  293 (14, 223, 354, 532)  0.27 
Echo RVSP (mmHg)  81 (41, 73, 90, 132)  74 (21, 51, 94, 145)  0.23 
RHC performed  13 (68%)  71 (73%)  0.78 
PAS (mmHg)  80 (50, 74, 86, 102)  75 (32, 65, 89, 152)  0.47 
mPAP (mmHg)  50 (26, 40, 52, 63)  49 (19, 38, 54, 100)  0.81 
Cardiac output (L/min)  4.0 (1.9, 2.8, 5.5, 8.8)  3.7 (1.3, 3.1, 4.6, 8.9)  0.89 
Cardiac index (L/min/m
2)  2.0 (1.1, 1.6, 2.7, 3.5)  2.2 (1.3, 1.8, 2.6, 4.7)  0.59 
PVR (dyne*sec/cm
5)  515 (358, 478, 1153, 1501)  610 (197, 476, 1005, 3692)  0.81 
-  P-values result from Fisher’s exact test or a Wilcoxon rank sum test. The sample median (minimum, 25
th percentile, 75
th percentile, maximum) is given for numerical variables. 
Information was unavailable for the following variables: PAS (N = 34), MPAP (N = 32), Cardiac output (N = 42), Cardiac index (N = 49), PVR (N = 46), and six minute walk test 
(N = 24). 
-  CTEPH = chronic thromboembolic pulmonary hypertension; WHO = World Health Organization; Echo = echocardiogram; RVSP = right ventricular systolic pressure; RCH = 
right heart catheterization; PAS = pulmonary artery systolic pressure; mPAP = mean pulmonary artery pressure; PVR = pulmonary vascular resistance. 88    The Open Respiratory Medicine Journal, 2009, Volume 3  Arunthari and Burger 
patients (17 out of 19) with CTEPH that had D-Dimer 
available were already on anticoagulation at the time of 
evaluation. Due to the study design which was a 
retrospective study we did not address or follow up D-Dimer 
levels after the diagnosis of CTEPH was made to allow for 
comparison. Further studies are required with larger number 
of participants utilizing one standard method for detecting 
CTEPH is needed. D-dimer itself though not appealing as a 
diagnostic test for CTEPH could have some light in 
following patients with already diagnosed CTEPH and 
suspecting of having an acute thromboembolic event thus 
this area would still need to be explored. 
CONCLUSION 
  In summary the low sensitivity and specificity for D-
dimer for the detection of CTEPH makes it an insensitive 
screening tool. Despite the high negative predictive value, D-
dimer alone should not be used to rule out CTEPH. 
Conversely, the presence of an elevated D-dimer in PAH is 
quite common, the significance of which was not studied. 
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ABBREVIATIONS 
CI =  Confidence  interval 
CTEPH  =  Chronic thromboembolic pulmonary  
     hypertension 
Echo =  Echocardiogram 
IPAH  =  Idiopathic pulmonary arterial hypertension 
mPAP  =  Mean pulmonary artery pressure 
NYHA  =  New York Heart Association 
NPV  =  Negative predictive value 
Table 3.  Patient Characteristics According to D-Dimer Test Availability, Separately for CTEPH and WHO Group 1 Patients 
 
CTEPH Patients  WHO Group 1 Patients 
Variable  D-Dimer Available  
(N = 19) 
D-Dimer Not Available  
(N = 15) 
D-Dimer Available  
(N = 97) 
D-Dimer Not Available  
(N = 137) 
Age  71 (31, 63, 74, 81)  67 (28, 51, 70, 82)  64 (21, 53, 73, 88)  60 (15, 48, 71, 86) 
Sex (Male)  10 (53%)  4 (27%)  20 (21%)  34 (25%) 
Race        
Caucasian  15 (79%)  13 (87%)  90 (93%)  119 (87%) 
African American  4 (21%)  2 (13%)  6 (6%)  15 (11%) 
Other  0 (0%)  0 (0%)  1 (1%)  3 (2%) 
WHO class        
1  1 (5%)  1 (7%)  4 (4%)  10 (7%) 
2  3 (16%)  3 (20%)  24 (25%)  29 (21%) 
3  13 (68%)  7 (47%)  56 (58%)  81 (59%) 
4  2 (11%)  4 (27%)  13 (13%)  17 (12%) 
Six minute walk test (meters)  319 (126, 266, 407, 460)  206 (206, 206, 206, 206)  293 (14, 223, 354, 532)  270 (51, 208, 348, 561) 
Echo RVSP (mmHg)  81 (41, 73, 90, 132)  79 (43, 60, 92, 125)  74 (21, 51, 94, 145)  77 (32, 55, 99, 140) 
RHC performed  13 (68%)  8 (53%)  71 (73%)  92 (67%) 
PAS (mmHg)  80 (50, 74, 86, 102)  83 (47, 69, 92, 159)  75 (32, 65, 89, 152)  80 (32, 67, 96, 138) 
mPAP (mmHg)  50 (26, 40, 52, 63)  48 (32, 46, 53, 76)  49 (19, 38, 54, 100)  49 (20, 41, 60, 93) 
Cardiac output (L/min)  4.0 (1.9, 2.8, 5.5, 8.8)  4.5 (3.8, 4.0, 4.7, 5.9)  3.7 (1.3, 3.1, 4.6, 8.9)  3.9 (1.3, 3.3, 4.8, 9.3) 
Cardiac index (L/min/m
2)  2.0 (1.1, 1.6, 2.7, 3.5)  1.8 (1.7, 1.7, 1.8, 1.8)  2.2 (1.3, 1.8, 2.6, 4.7)  2.3 (0.8, 1.8, 2.9, 4.9) 
PVR (dyne
*sec/cm
5)  515 (358, 478, 1153, 1501)  620 (294, 531, 651, 813)  610 (197, 476, 1005, 3692)  726 (82, 429, 934, 2238) 
-  The sample median (minimum, 25
th percentile, 75
th percentile, maximum) is given for numerical variables. Information was unavailable for the following variables: PAS (N = 88), 
MPAP (N = 84), Cardiac output (N = 118), Cardiac index (N = 132), PVR (N = 127), and six minute walk test (N = 142). 
-  CTEPH = chronic thromboembolic pulmonary hypertension; WHO = World Health Organization; Echo = echocardiogram; RVSP = right ventricular systolic pressure; RCH = 
right heart catheterization; PAS = pulmonary artery systolic pressure; mPAP = mean pulmonary artery pressure; PVR = pulmonary vascular resistance. D-Dimer in Chronic Thromboembolic Pulmonary Hypertension  The Open Respiratory Medicine Journal, 2009, Volume 3    89 
PAH =  Pulmonary  arterial  hypertension 
PAS  =  Pulmonary artery systolic pressure 
PH =  Pulmonary  hypertension 
PPV  =  Positive predictive value 
PVR  =  Pulmonary vascular resistance 
RCH  =  Right heart catheterization 
RVSP  =  Right ventricular systolic pressure 
V/Q  =  Ventilation and perfusion 
WHO  =  World Health Organization 
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